| Median (IQR) |
Rosiglitazone (n=34) |
Placebo (n=37) |
| Age in years |
47 (44, 52) |
52 (44, 54) |
| Men, N (%) |
29 (85) |
30 (81) |
| White, N (%) |
19 (56) |
17 (45) |
| CD4+ cell count, cells/mm3 |
596 (437, 706) |
690 (422, 860) |
| Nadir CD4+ cell count, cells/ mm3 |
205 (98, 271) |
123 (64, 247) |
| HIV-1 RNA <50 copies/mL, N (%) |
28 (82) |
29 (78) |
| Duration HIV diagnosis (months) |
146 (122, 194) |
170 (122, 231) |
| Duration on ART (months) |
114 (96, 127) |
105 (74, 123) |
| Duration on tNRTI (months) |
65 (48, 59) |
69 (24, 83) |
| Duration off tNRTI (months) |
47 (14, 59) |
42 (11, 64) |
| NNRTI at study entry, N (%) |
15 (44) |
14 (37) |
| PI at study entry, N (%) |
19 (56) |
23 (62) |
| Limb fat, grams |
4695.9 (3643.6, 7758.3) |
5966.7 (3514.3, 8434.7) |
| BMI, kg/m2 |
25.3 (22.5, 30.8) |
25.8 (22.8, 27.9) |
| sTNFR-I, pg/mL |
773.5 (597.0, 957.0) |
701.5 (573.1, 891.0) |
| sTNFR-II, pg/mL |
564.0 (232.0, 1247.0) |
605.0 (315.0, 1208.2) |
| IL-6 , pg/mL |
6.0 (2.0, 13.3) |
6.0 (3.0, 10.5) |
| hs CRP, mg/L |
7.6 (4.1, 18.1) |
3.2 (1.2, 14.7) |
| F2 isoprostanes, ng/mL |
0.032 (0.024, 0.043) |
0.032 (0.027, 0.046) |
| mtDNA, copies/ cell |
168 (143, 214) |
205 (166,222) |
# Significant difference between the groups (p=0.04) |
